NASDAQ-listed company Theravance Biopharma hopes to further establish its presence by expanding its Irish employee base.
October brought with it some wonderful job opportunities, with 1,600 jobs announced at the beginning of the month and another 490 revealed in later weeks, 380 of which were just in time for Halloween.
November has begun in a way that inspires further optimism, grâce à Theravance Biopharma. The pharmaceutical firm has opened a new corporate office in Dublin, with 30 new highly skilled positions now available.
The biopharmaceutical company is seeking new hires in areas such as clinical development, finance and technical operations. It hopes to fill these positions within the next two years.
An Tánaiste and Minister for Business, Enterprise and Innovation Frances Fitzgerald, TD, and other IDA Ireland executives joined members of the Theravance board of directors and employees at the opening ceremony.
Fitzgerald said: “The pharmaceutical industry makes a huge contribution to the Irish economy in terms of jobs and manufacturing exports, and is one of our fastest-growing sectors.
“My department through IDA Ireland is keen to attract new dynamic pharmaceutical companies like Theravance Biopharma, who will broaden the reach of the industry here and generate new opportunities.”
Chair and CEO of Theravance, Rick Winningham, said of the announcement: “The opening of our new office in Dublin demonstrates the increasingly important role that Theravance Biopharma plays in the global biopharmaceutical business, as we work with purpose to translate our science into therapeutics that can help patients around the world.”
Theravance’s first commercial product, Telavancin (trade name Vibativ), first received FDA approval in September 2009 and has since been approved in the US and Europe to treat hospital-acquired infections such as nosocomial pneumonia and MRSA.
The company has also developed Revefenacin, a drug to treat the common ailment chronic obstructive pulmonary disease (COPD). Revefenacin recently completed phase three clinical trials.
